An Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter Disease

Summary

Fosigotifator is an investigational drug being researched for the treatment of Vanishing White Matter disease in adult, pediatric and infant participants. This is a 201-week, open-label, multiple cohort study enrolling adults, pediatric and infant participants with Vanishing White Matter disease. Participants will attend regular visits during the course of the study and complete medical assessments, blood tests, questionnaires, and be evaluated for side effects.

Timeline

Start

2023-03-13

Primary completion

2027-11

Completion

2035-10

Drugs

Indications